News | Atrial Fibrillation

May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in patients ...

Home May 18, 2018
Home
Heart Rhythm Society (HRS) live electrophysiology (EP) procedure case at the 2018 annual meeting. #HRS2018
Feature | HRS | Dave Fornell

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) ...

Home May 18, 2018
Home
Atrial fibrillation ablation using the Abbott Ensite electro mapping system. CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy. #HRS2018
Feature | Atrial Fibrillation

May 16, 2018 – The first results of the randomized, multicenter, long-term, international CABANA clinical trial were ...

Home May 17, 2018
Home
News | EP Lab

May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics as ...

Home May 17, 2018
Home
News

Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during the annual Prague Workshop on Catheter Ablation, April 21-24 in Prague, Czech Republic.

Home May 17, 2018
Home
News | ECG Monitoring Services

A new study published in JAMA Cardiology used the Zio continuous cardiac monitoring system by iRhythm to provide a comprehensive picture of the burden of atrial fibrillation (AF) in patients. Utilizing this data in combination with electronic health record data, the researchers concluded that an increase in AF burden is independently associated with a higher risk of ischemic stroke and arterial thromboembolism in patients who are not taking anticoagulant medication.

Home May 17, 2018
Home
Heart Rhythm Society (HRS) Offers Recommendations to Prepare for Cybersecurity Threats to Cardiac Implantable Devices in new consensus document. #HRS2018
Feature | Cybersecurity

May 16, 2018 — The Heart Rhythm Society (HRS) released communication recommendations to assist healthcare professionals ...

Home May 16, 2018
Home
News | EP Lab

May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced ...

Home May 16, 2018
Home
Technology | Patient Monitors

Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care pathway monitoring system to monitor atrial fibrillation (AF) patients’ sleep apnea management status and compliance with continuous positive airway pressure (CPAP) devices on demand.

Home May 16, 2018
Home
News | Sudden Cardiac Arrest

May 16, 2018 — A new study shows that women exposed to particular matter (PM) and lower temperatures for even a short ...

Home May 16, 2018
Home
Blog | Cardiovascular Business

“Disruptive innovation” is all the buzz. Repealing the Affordable Care Act (ACA) is so last year. Well, disrupt this ...

Home May 16, 2018
Home
How coronary artery plaque forms and becomes a vulnerable plaque leading to a heart attack.
Feature | Brian Kolski, M.D., FACC

As a cardiologist practicing at the Orange County Heart Institute and St. Joseph Hospital in Orange, my mission is to ...

Home May 16, 2018
Home
News | Heart Failure

Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive implanted interatrial shunt device for treating patients with severe symptomatic heart failure (HF). The financing round was led by Deerfield Management, along with participation from new investors – healthcare funds Endeavour Vision, Quark Venture and Aperture Venture Partners. All of V-Wave's existing major investors are also participating in this round, including strategic investors Johnson & Johnson Innovation (JJDC Inc.) and Edwards Lifesciences, along with BRM Group, Pontifax, Pura Vida Investments, TriVentures, BioStar Ventures and Israel Secondary Fund.

Home May 16, 2018
Home
News | Implantable Cardioverter Defibrillator (ICD)

Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of inappropriate shocks using the Smart Pass sensing filter with the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System. The real-world data were presented during a late-breaking clinical trial at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, May 9-12 in Boston. The results demonstrated that when the sensing filter was in use, the rate of inappropriate shocks was reduced to 4.3 percent at one year.

Home May 16, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and new ...

Home May 15, 2018
Home
Subscribe Now